In addition, a selective MEK inhibitor, AZD6244 (25 mg/kg), showed approximately 30–40% greater anti-cancer efficacy with sorafenib (25 mg/kg) compared with the sorafenib-treated group in patient-derived xenograft models [38]. This evidence concerns the gene MAP2K7 and cancer.